Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Set To Grow From $8.85 Billion In 2026 To $21.34 Billion By 2030 At A CAGR Of 24.6%
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Revenue Outlook: What CAGR Is Expected Through 2030?
The contract development and manufacturing organization (CDMO) sector focused on cell and gene therapies has experienced remarkable expansion lately, projecting a leap from a valuation of $6.92 billion in 2025 to $8.85 billion in 2026, spurred by a compound annual growth rate (CAGR) of 27.8%. This surge during the past period has been fueled by several factors, including a greater reliance on external partners for manufacturing advanced therapies, the constrained internal manufacturing capacities of many organizations, the proliferation of emerging biotechnology firms, a heightened focus on developing treatments for rare diseases, and an escalating demand for highly specialized skills within the industry.
The cell and gene therapy contract development and manufacturing organization (CDMO) market is poised for substantial expansion, anticipating a surge to $21.35 billion by 2030, propelled by a 24.6% compound annual growth rate (CAGR). This projected expansion over the forthcoming years is fueled by several key factors: the increasing commercial viability of gene-modified therapeutic approaches, a heightened need for adaptable manufacturing capabilities, the broadening scope of international CDMO collaborations, escalating investments poured into cell therapy development pipelines, and a growing number of regulatory endorsements for cutting-edge therapies. Within this forecast period, discernible trends include CDMOs broadening their service portfolios to encompass the entire development lifecycle, a greater requirement for manufacturing support at a commercial scale, the increasing utilization of sophisticated gene editing technologies, a pronounced emphasis on expediting development schedules, and a more robust incorporation of regulatory support services.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp
Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Industry Drivers: What Is Driving Revenue Growth?
The increasing incidence of cancer is anticipated to be a significant catalyst for the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market. Cancer, a collective term for diseases involving the aberrant proliferation and dissemination of cells within the organism, is on the rise due to demographic shifts towards older age groups, alterations in daily habits, environmental factors, and advancements in diagnostic capabilities. Cell and gene therapy CDMOs play a crucial role in addressing the growing burden of cancer by pioneering the development and production of cutting-edge, individualized therapies that yield superior effectiveness and improved patient prognoses. Illustrating this trend, data from the Australian Institute of Health and Welfare, a governmental body in Australia, indicated that in 2023, an estimated 165,000 individuals in Australia received a new cancer diagnosis, a figure translating to more than 450 daily occurrences, with males accounting for approximately 55% of these diagnoses. Consequently, the escalating rate of cancer diagnoses is a primary driver for the cell and gene therapy CDMO market’s growth.
Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Categorization By Product Type And Application
The cell and gene therapy contract development and manufacturing organization (cdmo) market covered in this report is segmented –
1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy
2) By Phase: Phase 1, Phase 2, Phase 3
3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications
Subsegments:
1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy
2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy
3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy
#Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Growth Trends: What Is Influencing The Future Outlook?
Leading entities within the cell and gene therapy contract development and manufacturing organization (CDMO) sector are concentrating on broadening their service offerings by incorporating sophisticated technologies like PluriMatrix, aiming to elevate the manufacturability, operational effectiveness, and product integrity of cell-derived goods. PluriMatrix represents a proprietary platform engineered for the high-volume generation of cell-based therapeutics. This pioneering technology enables the three-dimensional expansion of cells at an industrial scale, thereby ensuring substantial output and uniform quality via a process that is automated, entirely regulated, and thoroughly verified. Illustrating this strategic move, Pluri, a biotechnology firm headquartered in Israel, announced in January 2024 the establishment of PluriCDMO, a new operational segment dedicated to providing contract manufacturing services for cell therapies. This newly formed business unit comprises a significant 47,000-square-foot facility operating under good manufacturing practice (GMP) standards for cell therapy production. Pluri’s recently launched division is equipped to deliver comprehensive support spanning from initial preclinical investigations through advanced clinical phases and eventual market entry, encompassing the entire spectrum of process and analytical development, scaling up manufacturing, validation procedures, logistical management, automation integration, and the execution of regulatory-compliant comparability studies, as outlined in a company press release. The division capitalizes on Pluri’s state-of-the-art PluriMatrix technology to deliver advanced manufacturing capabilities for cell therapies.
Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Company Landscape And Strategic Competition
Major companies operating in the cell and gene therapy contract development and manufacturing organization (cdmo) market are Lonza Group, Catalent Inc, Thermo Fisher Scientific Inc, Samsung Biologics Co Ltd, WuXi Biologics, AGC Biologics, FUJIFILM Diosynth Biotechnologies, Oxford BioMedica Plc, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Avid Bioservices Inc, Charles River Laboratories International Inc, VGXI Inc, Genezen Laboratories Inc, OmniaBio Inc, Pluri Inc, Cell and Gene Therapy Catapult, BioVectra Inc, Porton Advanced Solutions Ltd
Access The Complete Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Report:
Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Leading Geography: Which Region Generates The Most Revenue?
North Americawas the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
